| Patient | Zelda Fitzgerald |
|---|---|
| Date of birth | 1900-07-24 |
| Identifiers | MRN HR-ET004-SYN-TD; SSN (made up) 000-04-8712 |
| Document date | 1930-10-26 |
| Author | Margot Ellery, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Six-month review: maintenance treatment, lithium monitoring, and movement check. [S]
Ms. Fitzgerald returns six weeks after her preventive visit, about six months after the episode. She has had no manic, depressive, or psychotic symptoms. She takes lithium 300 mg twice daily and aripiprazole 10 mg daily. The intrauterine system has caused only light spotting. Her HPV, HIV, hepatitis C, chlamydia and gonorrhea tests from the preventive visit were all negative. She dances about four hours a day, has a full rest day each week, eats to plan, and her periods remain regular. She sleeps eight hours and has finished a short story. She asks whether she will need both medicines for life. She has had no thoughts of suicide or self-harm. [S]
| Element | Detail |
|---|---|
| Mood and psychosis | No symptoms; PHQ-9 3 |
| Medicines | Lithium 300 mg twice daily; aripiprazole 10 mg daily; levonorgestrel intrauterine system |
| Results from the preventive visit | HPV, HIV, hepatitis C, chlamydia and gonorrhea tests negative |
| Dance and periods | About four hours a day with a rest day; periods regular |
| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | Energy good; weight up slightly as planned |
| Genitourinary | Negative | Light spotting only; no pelvic pain; no increased urination |
| Neurological | Negative | Faint tremor when tired; no restlessness or abnormal movements |
| Psychiatric | Negative | Mood steady; no manic or psychotic symptoms; no thoughts of suicide or self-harm |
4 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Risperidone 2 mg oral tablet, one tablet by mouth at bedtime (started in hospital) | One tablet by mouth at bedtime | Oral route | 1930-04-20 to 1930-06-08 | completed | S |
| Lithium carbonate 300 mg oral capsule, one capsule by mouth twice daily | One capsule by mouth twice daily | Oral route | 1930-05-18 | active | S |
| Risperidone 1 mg oral tablet, one tablet by mouth at bedtime for one week, then stop | One tablet by mouth at bedtime for one week | Oral route | 1930-06-08 to 1930-06-15 | completed | S |
| Aripiprazole 10 mg oral tablet, one tablet by mouth once daily | One tablet by mouth once daily | Oral route | 1930-06-08 | active | S |
| Folic acid 0.4 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 1930-09-14 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 1930-10-26 | Body height | 165 | cm | S |
| 1930-10-26 | Body weight | 52.4 | kg | S |
| 1930-10-26 | Body mass index (BMI) [Ratio] | 19.2 | kg/m2 | S |
| 1930-10-26 | Systolic blood pressure | 110 | mm[Hg] | S |
| 1930-10-26 | Diastolic blood pressure | 70 | mm[Hg] | S |
| 1930-10-26 | Heart rate | 68 | /min | S |
| 1930-10-26 | Respiratory rate | 14 | /min | S |
| 1930-10-26 | Body temperature | 36.5 | Cel | S |
| 1930-10-26 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 1930-10-26 | Sodium [Moles/volume] in Serum or Plasma | 139 | mmol/L | 135-145 mmol/L | Normal | S |
| 1930-10-26 | Potassium [Moles/volume] in Serum or Plasma | 4 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 1930-10-26 | Creatinine [Mass/volume] in Serum or Plasma | 0.79 | mg/dL | 0.59-1.04 mg/dL | Normal | S |
| 1930-10-26 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1925)/1.73 sq M | 103 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 1930-10-26 | Lithium [Moles/volume] in Serum or Plasma | 0.72 | mmol/L | Maintenance target 0.6 to 0.8 mmol/L; above 1.2 mmol/L is above the therapeutic range | Normal | S |
| 1930-10-26 | Thyrotropin [Units/volume] in Serum or Plasma | 3.1 | m[IU]/L | 0.45-4.5 mIU/L | Normal | S |
| 1930-10-26 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 3 | {score} | S |
Vital signs recorded on 1930-10-26; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well; weight 52.4 kg, BMI 19.2; blood pressure 110/70, pulse 68 |
| Neck | Thyroid not enlarged |
| Neurological | AIMS score 0: no abnormal movements of the face, lips, jaw, tongue, limbs, or trunk; faint fine postural tremor; no akathisia |
| Psychiatric | Euthymic and engaged; organized; no psychotic or manic features |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| First episode of psychosis with marked mood symptoms: about three weeks of little sleep, rapid speech, racing thoughts, grandiose plans and very long training days, then a voice commenting on her dancing and a belief that she was being watched and tested; tearful low mood since discharge. Diagnosis provisional; differential: bipolar I disorder with psychotic features, schizoaffective disorder (bipolar type), and schizophreniform disorder or schizophrenia, depending on whether the psychosis ever occurred apart from the mood symptoms. Synthetic modern episode linked to her documented first hospitalization | resolved | provisional | F29 | S — Synthetic modern coding of the documented first breakdown. Unspecified psychosis is coded until the course shows how the psychosis relates to the mood symptoms; superseded at the three-month visit. |
| Bipolar I disorder, most recent episode manic with psychotic features, in full remission: the working diagnosis at three months, when her history, her journal, and her roommate's account (given with her consent) showed that the voice and the belief she was watched began only after weeks of manic symptoms and ended with them, with no psychosis since. Remains provisional: it would be revised to schizoaffective disorder if psychosis ever lasted two weeks or more without a mood episode. Synthetic modern episode linked to the documented breakdown and its retrospective interpretations | active | provisional | F31.74 | S — Synthetic modern diagnosis made from the course; the historical diagnoses stay in the claims. |
| Secondary amenorrhea: no periods for about four months before admission, during very heavy dance training at a low weight (BMI 18.7), with prolactin raised on risperidone; pregnancy test negative | resolved | confirmed | N91.1 | S — Synthetic presenting finding linked to her documented training; resolved when her periods returned. |
| Acute viral gastroenteritis (vomiting and watery diarrhea for two days, roommate with the same illness), with mild dehydration; resolved | resolved | confirmed | A08.4 | S — Synthetic acute infection; not a historical claim. |
| Lithium level above the therapeutic range (1.4 mmol/L) during dehydration, with nausea and a worse fine tremor, without confusion or unsteadiness; lithium held and restarted; resolved | resolved | confirmed | T43.595A | S — Synthetic medication adverse effect at a prescribed dose; ICD-10-CM classifies lithium salts with the other antipsychotics and neuroleptics. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Medication safety | Antipsychotic dose, adherence, and response | Every visit | Completed today | Aripiprazole 10 mg; full adherence; taper to be reviewed with psychiatry |
| Survey | Manic, depressive, and psychotic symptoms, and early warning signs | Every visit | Completed today | No manic, depressive, or psychotic symptoms |
| Examination | Akathisia, parkinsonism, and sedation | Every visit in the first months and after any dose change | Completed today | None |
| Examination | Abnormal Involuntary Movement Scale (AIMS) | Baseline, then every 6 months | Completed today | AIMS score 0 at six months; repeat in six months |
| Examination | Weight and BMI | Every visit for 6 months after starting or changing an antipsychotic (CMID: baseline, 4, 8, and 12 weeks, then quarterly) | Completed today | 52.4 kg (BMI 19.2), up 1.6 kg from intake as planned; quarterly from now |
| Examination | Blood pressure | Baseline, 12 weeks, then yearly | Completed today | 110/70 |
| Laboratory | Fasting glucose and A1c | Baseline, 12 weeks to 4 months, then yearly | Up to date | Normal at three months; next in a year |
| Laboratory | Fasting lipid panel | Baseline, 12 weeks to 4 months, then yearly | Up to date | Normal at three months; next in a year |
| Laboratory | Lithium level (12-hour trough) | 5 to 7 days after starting and after any change until stable, then every 3 to 6 months | Completed today | 0.72 mmol/L; every three to six months from now |
| Laboratory | Creatinine and eGFR on lithium | Baseline, every 2 to 3 months for 6 months, then every 6 to 12 months | Completed today | Creatinine 0.79 mg/dL, eGFR 103; sodium 139, potassium 4.0 mmol/L |
| Laboratory | TSH on lithium | Baseline, once or twice in the first 6 months, then every 6 to 12 months | Completed today | 3.1 mIU/L; every six to twelve months from now |
| Laboratory | Calcium on lithium | Baseline, then yearly | Up to date | Normal at three months; next in a year |
| Medication safety | Lithium side effects and sick-day rules | At the start and every visit | Completed today | Faint tremor only; sick-day plan current |
| Medication safety | Pregnancy prevention on lithium; valproate avoided | Before starting and at each visit until a reliable method is in place | Completed today | Levonorgestrel intrauterine system in place; folic acid daily |
| Survey | Depression measure (PHQ-9) | Monthly during acute treatment, every 2 to 4 weeks in continuation, then periodically | Completed today | PHQ-9 3, from 11 at intake: remission |
| Survey | Suicide-risk review, safety plan, lethal means, and the 988 Suicide & Crisis Lifeline | Every visit | Completed today | No thoughts of suicide or self-harm; safety plan and psychiatric advance directive current; the 988 Suicide & Crisis Lifeline in her phone |
| Self-management | Sleep | Every visit | Completed today | Eight hours at regular times |
| Self-management | Eating, exercise, and periods | Every visit while periods are absent or weight is low | Completed today | Periods regular; about four hours of dance a day with a rest day; SCOFF 0 at the preventive visit |
| Self-management | Coordinated specialty care engagement | Ongoing, for up to two to three years | Completed today | Therapist every two weeks; peer specialist monthly |
Goal progress:
Guideline basis: Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder (2018); The CANMAT and ISBD Guidelines for the Treatment of Bipolar Disorder: Summary and a 2023 Update of Evidence (2023); The American Psychiatric Association Practice Guideline for the Treatment of Patients With Schizophrenia, Third Edition (2020); Consensus development conference on antipsychotic drugs and obesity and diabetes (2004); Recovery After an Initial Schizophrenia Episode (RAISE): coordinated specialty care for first-episode psychosis (2026); U.S. Selected Practice Recommendations for Contraceptive Use, 2024 (2024); VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024); CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026)
Follow-up: Psychiatry review with Dr. Langford next month about a slow aripiprazole taper. Visits every three months with lithium level, creatinine, and TSH. Calcium, glucose, A1c, lipids, and the AIMS as scheduled. [S]